Disparities in the use of antineoplastic immunotherapy in pediatric malignant adrenal tumors | Zendy

Shoag Jamie M. | Zendy; Podda Antonello | Zendy; Kobetz Erin N. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Disparities in the use of antineoplastic immunotherapy in pediatric malignant adrenal tumors

Author(s) -

Shoag Jamie M.,

Podda Antonello,

Kobetz Erin N.

Publication year - 2020

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.28522

Subject(s) - medicine , quartile , immunotherapy , odds ratio , oncology , food and drug administration , neuroblastoma , cancer , odds , confidence interval , logistic regression , environmental health , biology , genetics , cell culture

Dinutuximab is a costly life‐prolonging immunotherapy for high‐risk neuroblastoma. We used a large pediatric inpatient database to analyze the use of antineoplastic immunotherapy in patients with malignant adrenal tumors 1 year after Food and Drug Administration approval of dinutuximab for high‐risk neuroblastoma. On multivariate modeling, children of Black race (odds ratio [OR] 0.62, P = .04; referent non‐Black) and the lowest ZIP code income quartile (OR 0.74, P = .03; referent wealthier 3 quartiles) were significantly less like to receive antineoplastic immunotherapy. These results suggest substantial disparities in the distribution of a vital therapy in children with advanced cancer.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research